CD19 and acute lymphoblastic leukemia: In this experimental setup, mice were intravenously injected with 3 million hCD19+ B-ALL cells, followed by the administration of 10 million CD19, or control (EGFRvIII) CAR T cells 3 days later (Fig. 4A).